肺表面活性物质联合布地奈德治疗重症呼吸窘迫综合征早产儿的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of pulmonary surfactant(PS)combined with Budesonide in the treatment of premature infants with neonatal respiratory distress syndrome(NRDS)and its effect on arterial blood gas status.Methods A total of 98 premature infants with severe NRDS admitted to Jinan Laiwu People′s Hospital from July 2019 to July 2020 were selected and divided into two groups according to random number table method,with 49 cases in each group.Both groups were given routine treatment,the control group was additionally treated with PS,and the observation group was additionally treated with Budesonide on the basis of PS treatment.The arterial blood gas status,ventilator related parameters,ventilation related indexes and adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in arterial blood gas index and ventilator related parameters between the two groups(P>0.05).The partial blood oxygen pressure(PaO2)and oxygenation index(OI)of the two groups after treatment were higher than those before treatment,and the partial blood carbon dioxide pressure(PaCO2)of the two groups after treatment was lower than that before treatment,the PaO2 and OI of the observation group after treatment were(81.79±6.79)mmHg and(283.69±19.13)mmHg,which were higher than those of the control group,which were(76.68±6.34)and(264.41±17.76)mmHg,PaCO2 of the observation group after treatment was(40.52±4.58)mmHg,lower than that of the control group of(45.31±4.62)mmHg,and the differences were statistically significant(P<0.05).After treatment,the peak inspiratory pressure(PIP),inhaled oxygen concentration(FiO2)and respiratory rate(RR)of the two groups were all lower than those before treatment,and the PIP,FiO2 and RR of the observation group were(17.89±1.86)cmH2O,(29.68±4.05)% and(35.42±4.31)times/min after treatment,which were lower than those in the control group of(19.65±2.02)cmH2O,(33.71±4.27)%,(40.28±4.65)times/min,and the differences were statistically significant(P<0.05).The invasive ventilation time of the observation group was(3.25±0.42)d,weaning time of the observation group was(27.69±3.65)d,and hospitalization time of the observation group was(40.13±5.62)d,which were all shorter than those of the control group of(4.51±0.86),(31.14±3.85)and(46.85±5.79)d,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05),and no serious adverse reactions occurred in the two groups,which did not affect the treatment after symptomatic treatment.Conclusion PS combined with Budesonide can enhance the treatment effect of children with severe NRDS,improve the arterial blood gas index,correct the body′s hypoxia state,reduce the burden of respiratory support,and shorten the weaning time.It is safe and reliable.

Key words： Neonatal respiratory distress syndrome Premature infant Pulmonary surfactant Budesonide Arterial blood gas

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MENG Zhao-hui

Cite this article:

MENG Zhao-hui. Effect of pulmonary surfactant combined with Budesonide in treatment of premature infants with neonatal respiratory distress syndrome[J]. 中国当代医药, 2021, 28(25): 163-166.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I25/163

[1]	王君，王建民，崔福英，等.不同布地奈德给药方式联合PS对呼吸窘迫综合症患儿肺功能及安全性的影响[J].国际呼吸杂志，2019，39（15）：1163-1168.
[2]	聂振清，陈晓燕.机械通气联合不同肺表面活性物质在新生儿呼吸窘迫综合征中的价值[J].安徽医药，2019，23（6）：1222-1225.
[3]	肖小芳，彭好.肺表面活性物质在新生儿呼吸窘迫综合征的应用[J].医学综述，2020，26（7）：1379-1383，1389.
[4]	廖亮荣.机械通气与经鼻塞持续正压通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的疗效分析[J].中国妇幼保健，2018，33（2）：432-434.
[5]	平莉莉，张淑彦，翟淑芬.二联支气管药物滴注方案对重症呼吸窘迫综合征早产儿临床预后的影响[J].中国医师进修杂志，2019，42（2）：154-157.
[6]	王卫平，孙锟，常立文.儿科学[M].9 版.北京：人民卫生出版社，2018：110.
[7]	林梅，朱晓波，薛江.肺表面活性物质联合不同通气方式对重症新生儿呼吸窘迫综合征的效果分析[J].中国儿童保健杂志，2019，27（5）：561-564.
[8]	张慧，李锋，张树清.鼻腔持续与间歇正压通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的疗效[J].儿科药学杂志，2020，26（9）：28-31.
[9]	黄方，陈霞，饶绘.高频振荡通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征[J].川北医学院学报，2017，32（3）：332-335.
[10]	魏小娣，樊婷.经鼻持续正压通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征临床观察[J].解放军医药杂志，2017，29（11）：61-64.
[11]	冯炽光.肺表面活性物质对早产呼吸窘迫综合征患儿血清中氧化应激产物及水通道蛋白水平的影响[J].中国妇幼保健，2017，32（16）：3836-3840.
[12]	杨锦明.不同肺表面活性物质治疗新生儿呼吸窘迫综合征的临床效果对比[J].广西医学，2017，39（6）：825-827.
[13]	张佩，夏世文，祝华平，等.经胃管微创注入肺表面活性物质技术治疗新生儿呼吸窘迫综合征的效果[J].中国医药导报，2020，17（6）：95-98，114.
[14]	周栩平，周静，胡冰，等.布地奈德联合肺表面活性物质对重症呼吸窘迫综合征早产儿近期疗效，血氧指标及支气管肺发育不良发生风险的影响[J].儿科药学杂志，2019，25（11）：27-30.
[15]	邓黎静，彭华保，龚晓琴.布地奈德联合肺泡表面活性物质气管内滴入治疗早产儿重症呼吸窘迫综合症的疗效研究[J].中南医学科学杂志，2018，46（1）：91-94.